Author: Editor

Non-small-cell lung carcinoma (NSCLC) is an important area for the development and marketing of immuno-oncology (IO) drugs for most large pharmaceutical companies in space, both as monotherapy and in conjunction with other IO agents. The market and use of IO therapies in NSCLC for targeted therapies and chemotherapies is expected to continue to grow, and IO therapies will account for more than 50%.  Tajekesa Chapman, Senior Oncology and Hematology Analyst at GlobalData, comments: “AstraZeneca recently announced that its combination of Imfinzi (durvalumab) + chemotherapy, with or without tremelimumab, met its key endpoint of improving progression-free survival (PFS) when compared to…

Daniel M. Rotroff, PhD of @CleClinicMD answers commonly asked questions to anti-PD-1/PD-L1 antibody immunotherapy. _________ Read here: https://ascopubs.org/doi/full/10.1200/JCO.19.01712

Daniel M. Rotroff, PhD of @CleClinicMD discusses the response to anti-PD-1/PD-L1 antibody immunotherapy. __________ Read here: https://ascopubs.org/doi/full/10.1200/JCO.19.01712

    Philadelphia, PA (November 20, 2019) – Oncoceutics, Inc. announced that new  data will be presented  on the efficacy and mechanism of action of  imipridones ONC201 and ONC206 at the 24th Annual Scientific Meeting of the Society of Neuro-Oncology, to be held November 20th-24th in Phoenix, Arizona. These data will highlight exciting findings that have emerged over the past year, including: ·       Updated clinical results for ONC201 in pediatric and adult H3 K27M-mutant gliomas ·       Extension of ONC201 activity to other brain tumors ·       Synergy antitumor activity of ONC201 in combination with other treatments ·       Activity of ONC206 in…

Craig Slingluff, MD of @UVACancerCenter answers the study design and what is next for phase III data for a melanoma vaccine, seviprotimut-L. _____________ — MAVIS Study Identifies Most Responsive Patient Subpopulations, Supporting the Continued Study of Adjuvant Treatment in Localized Melanoma Patients — Polynoma LLC, a U.S. immuno-oncology focused biopharmaceutical company and wholly-owned subsidiary of Hong Kong-listed CK Life Sciences Int’l., (Holdings) Inc., is presenting clinical data from MAVIS (Melanoma Antigen Vaccine Immunotherapy Study), its ongoing Phase III clinical study of seviprotimut-L, an investigational melanoma vaccine candidate, on November 8 at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting…

Philadelphia, PA (Nov. 19, 2019) – Oncoceutics, Inc. announced a publication in the journal Nature Communications demonstrating selective antagonism of the G-protein coupled receptor (GPCR) dopamine receptor D2 (DRD2) by Oncoceutics’ lead candidate imipridone, ONC201.ONC201 was found to specifically bind and antagonize DRD2, and its functionally redundant family member DRD3, without affecting other dopamine receptors, other GPCRs, nuclear hormone receptors, kinases, or other drug targets of FDA-approved cancer therapies. Additionally, a biologically inactive isomer of ONC201 did not antagonize DRD2, indicating that antagonism of this receptor may be linked to anti-cancer efficacy as shown in other publications (Clinical Cancer Research…

Philadelphia, PA (November 13, 2019) – Oncoceutics, Inc. announced that results from the second and third cohort of the Phase II trial for patients with recurrent glioblastoma treated with the company’s lead imipridone, ONC201, were recently published in the journal Neuro-Oncology. This manuscript represents the third publication among a series of reports demonstrating durable radiographic regressions with ONC201 in patients with H3 K27M-mutant glioma. The study (NCT02525692) also demonstrated that weekly oral administration of ONC201 given as a single agent was well-tolerated, achieved therapeutic intratumoral concentrations, and intratumoral pharmacodynamic activity in adult recurrent glioblastoma patients. ONC201 achieved intratumoral concentrations that exceeded…

Bryan Lewis, President KidneyCan discusses An Advocates Perspective to Increasing Funding Resources at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Craig Slingluff, MD of @UVACancerCenter discusses the phase III data for a melanoma vaccine, seviprotimut-L. ____________ — MAVIS Study Identifies Most Responsive Patient Subpopulations, Supporting the Continued Study of Adjuvant Treatment in Localized Melanoma Patients — Polynoma LLC, a U.S. immuno-oncology focused biopharmaceutical company and wholly-owned subsidiary of Hong Kong-listed CK Life Sciences Int’l., (Holdings) Inc., is presenting clinical data from MAVIS (Melanoma Antigen Vaccine Immunotherapy Study), its ongoing Phase III clinical study of seviprotimut-L, an investigational melanoma vaccine candidate, on November 8 at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland. MAVIS is an adaptive phase III multicenter, double-blind, placebo-controlled trial to assess the safety and efficacy of seviprotimut-L, with primary endpoints of recurrence-free survival (RFS) and overall survival (OS) in patients with American Joint Cancer Committee (AJCC) Stage IIB / C, IIIA, IIIB / C melanoma at high risk of recurrence following definitive surgical resection. Highlights of…

Patients show improvements in blood vessels and physical ability after 8-week regimen — While exercise offers benefits for a wide range of health conditions, it has historically been considered too dangerous for people living with sickle cell disease (SCD). However, a new study published today in the journal Blood adds to mounting evidence that low-to moderate-intensity exercise may be not only safe, but beneficial for these patients. SCD affects how blood flows through the body. For those with SCD, strenuous physical activity increases blood flow and can lead to serious complications including heart problems and episodes of severe pain known as vaso-occlusive crises. While many…

Christopher Wood, MD from MDAnderson holds a kidney cancer tumor board with real cases from the Kidney Cancer Association annual meeting in Miami, FL 2019

Hans Hammers MD, PhD presents Radiation to Prime the Immune System Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Neal Shore, MD of Carolina Urologic Research Center @UrologyUS on how the ProVent trial might change the AS treatment landscape. ________ Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, announced early completion of patient enrollment of its Phase 3 ProVent clinical trial. More than 450 subjects were randomized in the large-scale clinical trial, which is evaluating the effectiveness of sipuleucel-T (PROVENGE®) in reducing disease progression in men with early-stage prostate cancer on active surveillance (AS). “The rapid pace of enrollment in the ProVent trial is a significant milestone for Dendreon, and underscores a strong interest…

Neal Shore, MD of Carolina Urologic Research Center @UrologyUS on how the ProVent trial might change the AS treatment landscape. _________ Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, announced early completion of patient enrollment of its Phase 3 ProVent clinical trial. More than 450 subjects were randomized in the large-scale clinical trial, which is evaluating the effectiveness of sipuleucel-T (PROVENGE®) in reducing disease progression in men with early-stage prostate cancer on active surveillance (AS). “The rapid pace of enrollment in the ProVent trial is a significant milestone for Dendreon, and underscores a strong interest…

Neal Shore, MD of Carolina Urologic Research Center @UrologyUS on how the ProVent trial might change the AS treatment landscape. __________ Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, announced early completion of patient enrollment of its Phase 3 ProVent clinical trial. More than 450 subjects were randomized in the large-scale clinical trial, which is evaluating the effectiveness of sipuleucel-T (PROVENGE®) in reducing disease progression in men with early-stage prostate cancer on active surveillance (AS). “The rapid pace of enrollment in the ProVent trial is a significant milestone for Dendreon, and underscores a strong interest…

Neal Shore, MD of Carolina Urologic Research Center @UrologyUS provides insight on current treatment options for men in the phase 3 provent trial. __________ Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, announced early completion of patient enrollment of its Phase 3 ProVent clinical trial. More than 450 subjects were randomized in the large-scale clinical trial, which is evaluating the effectiveness of sipuleucel-T (PROVENGE®) in reducing disease progression in men with early-stage prostate cancer on active surveillance (AS). “The rapid pace of enrollment in the ProVent trial is a significant milestone for Dendreon, and underscores…

Neal Shore, MD of Carolina Urologic Research Center @UrologyUS discusses the phase 3 provent clinical trial. ____________ Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, announced early completion of patient enrollment of its Phase 3 ProVent clinical trial. More than 450 subjects were randomized in the large-scale clinical trial, which is evaluating the effectiveness of sipuleucel-T (PROVENGE®) in reducing disease progression in men with early-stage prostate cancer on active surveillance (AS). “The rapid pace of enrollment in the ProVent trial is a significant milestone for Dendreon, and underscores a strong interest by patients and physicians…

Robert Hapke, Katherine E. Beckermann MD/PhD, W. Kimryn Rathmell MD/PhD, and Scott M. Haake MD Vanderbilt-Ingram Cancer Center Vanderbilt University Medical Center presents Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma. Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Abhishek Tripathi MD Assistant Professor, Section of Hematology Oncology University of Oklahoma Stephenson Cancer Center Oklahoma City, OK presents Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Leigh Ellis Department of Oncologic Pathology Dana-Farber Cancer Institute Harvard Medical School presents Using Epigenetic Therapy to Enhance Immunotherapy Response in RCC Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Thai Ho Mayo Clinic Arizona presents Therapeutic targeting of the extracellular matrix in kidney cancer Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Charles G. Drake MD / PhD Director GU Medical Oncology Co-Director: Immunotherapy Program Associate Director for Clinical Research Professor of Oncology and Urology Herbert Irving Cancer Center at Columbia University presents Innate Cytokines and Myeloid Cells Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Aguirre A. de Cubas, Ph.D. Post-Doctoral Fellow WK Rathmell Lab Vanderbilt University Medical School presents DNA Demethylation promotes ERV expression and activation of immune signaling in renal cell cancer cells Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Haydn Kissick, Ph.D. Department of UrologyDepartment of Microbiology and Immunology presents The T-cell response to Kidney Cancer Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Arlene Sharpe M.D. Ph.D. Department of Immunology Harvard Medical School presents Discovery of new IO Targets Leveraging CRISPR Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Patient-reported ECOG performance status (PS) is lower than oncologist-reported PS and is associated with worse psychosocial outcomes. Cristiane Decat Bergerot, PhD Psychologist, Postdoctoral Fellow City of Hope Comprehensive Cancer Center And colleagues Paulo Bergerot, MD; Errol Philip, PhD; JoAnn Hsu, BS; Nazli Dizman, MD; Meghan Salgia; Dena Battle; Ulka Vaishampayan, MD; Matthew Loscalzo, LCSW; William Dale, MD, PhD; Sumanta K. Pal, MD Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.     cancer research, toxicity and response criteria of the eastern cooperative oncology group ecog About ECOG Performance Status: To conduct clinical cancer treatment trials effectively across…

Meredith M. Regan,1 Michael B. Atkins,2 Thomas Powles,3 Lillian Werner,4 Charlene Mantia,5 Shuo Yang,6 Jennifer L. Johansen,6 Sumati Rao,6 Kyna M. Gooden,6 David F. McDermott7 1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; 2Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; 3Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London; 4Dana-Farber Cancer Institute, Boston, MA; 5Beth Israel Deaconess Medical Center, Boston, MA; 6Bristol-Myers Squibb, Princeton, NJ; 7Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma 18th International Kidney…

Chung-Han Lee1, Amishi Y. Shah2, Vicky Makker1, Matthew Taylor3, David Shaffer4, James J. Hsieh5, Allen L. Cohn6, Chris DiSimone7, Alvaro Pinto Marin8, Drew Rasco9, Sara Gunnestad Ribe10, Donald A. Richards11, Daniel E. Stepan*, Corina E. Dutcus12, Jane Wu12, Emmett V. Schmidt13, Rodolfo Perini13, Robert Motzer1 1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2MD Anderson Cancer Center, University of Texas, Houston, TX, USA; 3Oregon Health and Science University; Portland, OR, USA; 4New York Oncology Hematology, Albany, NY, USA; 5Washington University School of Medicine, St. Louis, MO, USA; 6Rocky Mountain Cancer Center, Denver, CO, USA; 7Arizona Oncology Associates, Tucson, AZ,…

Steven P. Rowe, MD, PhD Division of Nuclear Medicine and Molecular Imaging Russell H. Morgan Department of Radiology and Radiological Science Johns Hopkins Medical Institutions, Baltimore, MD, USA presents 99mTc-Sestamibi SPECT CT for Renal Mass Characterization at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

I. Alex Bowman, MD Assistant Professor, Division of Hematology/Oncology UT Southwestern Medical Center, Dallas, TX Co-Authors: Marianna Dakanali, Guiyang Hao, Aditi Mulgaonkar, Payal Kapur, Xiankai Sun, Orhan K. Oz, James Brugarolas. present An Exploratory Study of 89Zr-DFO-Atezolizumab ImmunoPET CT at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Haris Zahoor, Akash Sali, Manju Aron, Imran Siddiqui, Bino Varghese, Steven Cen, Xiaomeng Lei, Anishka D’Souza, Austin Fullenkamp, Mihir Desai, Inderbir Gill, David Quinn, Vinay Duddalwar USC Norris Comprehensive Cancer Center discusses Radiomic Signatures of CD8+ T Cell Infiltration and PD-L1 Expression in Clear-Cell Renal Cell Carcinoma (ccRCC) at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Zhen J. Wang, MD Professor of Radiology Department of Radiology and Biomedical Imaging University of California, San Francisco discusses Hyperpolarized 13C Metabolic MRI of Renal Tumors at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Ivan Pedrosa, MD PhD Professor of Radiology, Urology, Advanced Imaging Research Center and Biomedical Engineering University of Texas Southwestern, Dallas, TX discusses Virtual Biopsy with MRI The Clear Cell Score at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Allan Pantuck, MD, MS, FACS Professor and Vice Chair, Urology Institute of Urologic Oncology David Geffen School of Medicine at UCLA discusses Carbonic Anhydrase IX (CAIX) Imaging for Renal Cell Carcinoma at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Martin H. Voss1, Arun Azad2, Aaron R. Hansen3, Jhanelle E. Gray4, Sarah J. Welsh5, Xuyang Song6, Ikbel Achour6, Heping Hu6, Lisa Lewis6, Farzana L. Walcott6, Sjoukje F. Oosting7 1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Monash Health, Melbourne, Australia; 3Princess Margaret Cancer Centre, Toronto, Canada; 4Moffitt Cancer Center, Tampa, FL, USA; 5Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; 6AstraZeneca, Gaithersburg, MD, USA; 7University Medical Center Groningen, University of Groningen, Groningen, The Netherlands Results from a Randomized Phase 1-2 Trial Evaluating the Safety and Antitumor Activity of Anti-PD-1 (MEDI0680) Anti-PD-L1 (Durvalumab) vs Anti-PD-1 (Nivolumab) Alone in Metastatic Clear…

Ritesh Kotecha1, Ronan Flippot2, Sujata Patil1, Taylor Nortman1, Annalisa Guida2, Ashley Foster1, Bernard Escudier2, Robert Motzer1, Laurence Albiges2, Martin Voss1 1Memorial Sloan Kettering Cancer Center, USA 2Institute Gustave Roussy, France discusses Incidence of Occult Brain Metastasis at Study Screening in Patients with Advanced Clear Cell Renal Cell Carcinoma at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Viraj Master MD PhD FACS Professor Fray F. Marshall Chair in Urological Research Department of Urology Director of Integrative Oncology and Survivorship Winship Cancer Institute Emory University discusses Optimal Role of Consolidative Surgery in the IO Era at the 18th International Kidney Cancer Symposium 2019, Miami, FL. _________ Interview here: https://www.oncologytube.com/video/consolidative-surgery-in-the-io-era-winshipatemory

Elad Sharon, MD, MPH Senior Investigator/Medical Officer Cancer Therapy Evaluation Program Division of Cancer Therapy & Diagnosis National Cancer Institute discusses Vulnerable Populations in Immuno-Oncology Research at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Tian Zhang, MD, MHS discusses Aiming to personalize immunotherapy with existing and emerging biomarkers at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

André P. Fay, MD, PhD Professor, PUCRS School of Medicine Chief, Medical Oncology Department – Oncoclínicas/HSL-PUCRS Visiting Scientist at Dana-Farber Cancer Institute/ Harvard Medical School discusses Optimal Management of Favorable Risk Clear Cell RCC Combination Therapy at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Walter Stadler, MD FACP Dean for Clinical Research Deputy Director Comprehensive Cancer Center University of Chicago discusses Favorable Risk Renal Cancer Of Course Monotherapy is the Obvious Right Answer at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Michael R. Harrison, MD Associate Professor of Medicine Duke Cancer Institute discusses Active Surveillance for Favorable Risk mRCC at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Deborah Maskens MA MSM International Kidney Cancer Coalition discusses Unmet Patient Needs: Results from IKCC Global Survey at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

David Braun, MD, PhD DF/HCC Kidney Cancer SPORE Harvard Medical School discusses Understanding CD8+ T Cell Function and Specificity in RCC at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Toni K. Choueiri, MD On Behalf of DF/HCC SPORE leadership PI: McDermott and Kaelin gives an overview of the Dana-Farber/Harvard Cancer Center Kidney Cancer SPORE A brief overview 2014-2019 at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Srinivas Malladi, Ph.D. Harold C. Simmons Comprehensive Cancer Center, Department of Pathology University of Texas Southwestern Medical Center, Dallas, TX discusses ccRCC – Invasion and Metastasis at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

James Brugarolas, M.D., Ph.D. Director, Kidney Cancer Program Principal Investigator, Kidney Cancer SPORE Sherry Wigley Crow Endowed Chair in Cancer Research Professor of Internal Medicine / Hematology-Oncology Cancer Biology, Genetics, Development and Disease University of Texas Southwestern Medical Center discusses UT Southwestern Kidney Cancer Program & SPORE at the 18th International Kidney Cancer Symposium 2019, Miami, FL. _______ Interview here: https://www.oncologytube.com/video/kidney-cancer-program-spore

Mark H. Michalski MD Executive Director, Center for Clinical Data Science Massachusetts General Hospital/Brigham and Women’s Hospital discusses How Artificial Intelligence Can Improve Cancer Care at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

W. Kimryn Rathmell, MD, PhD Professor of Medicine and Biochemistry; Director, Division of Hematology and Oncology Vanderbilt University Medical Center discusses Learning to Pivot: The Renal Cell Carcinomas at the 18th International Kidney Cancer Symposium 2019, Miami, FL.